-
公开(公告)号：US20130344085A1
公开(公告)日：2013-12-26
申请号：US13918755
申请日：2013-06-14
Applicant: Genentech, Inc.
Inventor： Yan WU , Cecilia Pui Chi CHIU , Daniel K. KIRCHHOFER , Andrew PETERSON , Ganesh A. KOLUMAM , Monica Kong BELTRAN , Paul MORAN , Wei LI , Xanthe LAM , Lin LUIS , Ada HUI , Whittemore TINGLEY , John Douglas DAVIS , Nageshwar R. BUDHA
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K39/39591 , A61K2039/505 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.
Abstract translation: 本发明提供抗PCSK9抗体，制剂，给药方案及其使用方法。
-
公开(公告)号：US20130129743A1
公开(公告)日：2013-05-23
申请号：US13651289
申请日：2012-10-12
Applicant: GENENTECH, INC.
Inventor： Yan WU , Menno van LOOKEREN-CAMPAGNE , Daniel KIRCHHOFER , Michael Terry LIPARI , Kenneth J. KATSCHKE, JR. , Paul M. MORAN , Scott STAWICKI , Wei-Ching LIANG
IPC: C07K16/40
CPC classification number: C07K16/40 , C07K2317/34 , C07K2317/76 , C07K2317/92
Abstract: The invention provides anti-HtrA1 antibodies and methods of using the same.
Abstract translation: 本发明提供抗HtrA1抗体及其使用方法。
-
公开(公告)号：US20220064286A1
公开(公告)日：2022-03-03
申请号：US17526338
申请日：2021-11-15
Applicant: Genentech, Inc.
Inventor： Jane L. GROGAN , Robert J. JOHNSTON , Yan WU , Wei-Ching LIANG , Patrick LUPARDUS , Mahesh YADAV , Dhaya SESHASAYEE , Meredith HAZEN
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61K45/06 , A61K38/17
Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
-
公开(公告)号：US20210301005A1
公开(公告)日：2021-09-30
申请号：US17205663
申请日：2021-03-18
Applicant: Genentech, Inc.
Inventor： Wei-Ching LIANG , Joseph R. ARRON , Daryle DEPIANTO , Wendy Green HALPERN , WeiYu LIN , Patrick J. LUPARDUS , Thirumalai Rajan RAMALINGAM , Dhaya SESHASAYEE , Tianhe SUN , Tulika TYAGI , Jia WU , Yan WU , Jian Ping YIN
Abstract: The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.
-
公开(公告)号：US20210032345A1
公开(公告)日：2021-02-04
申请号：US16854707
申请日：2020-04-21
Applicant: Genentech, Inc.
Inventor： Bryan IRVING , Henry CHIU , Heather MAECKER , Sanjeev MARIATHASAN , Sophie M. LEHAR , Yan WU , Jeanne CHEUNG
IPC: C07K16/28 , C07K16/30 , A61K31/7068 , A61K39/395 , A61K45/06 , C07K16/10 , C07K16/22 , A61K39/00
Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
-
Patent Agency Ranking
公开(公告)号：US20180100018A1
公开(公告)日：2018-04-12
申请号：US15809232
申请日：2017-11-10
Applicant: Genentech, Inc.
Inventor： Junichiro Sonoda , Yan WU
IPC: C07K16/28 , A61K45/06 , A61K39/395 , C07K16/40 , A61K39/00
CPC classification number: C07K16/2863 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/40 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/56 , C07K2317/75 , C07K2317/92
Abstract: The invention provides nucleic acid molecules encoding anti-fibroblast growth factor receptor-1 (FGFR1) antibodies and vectors and host cells comprising the nucleic acid molecules.
-
公开(公告)号：US20170158769A1
公开(公告)日：2017-06-08
申请号：US15266105
申请日：2016-09-15
Applicant: Genentech, Inc.
Inventor： Avi ASHKENAZI , Jing QING , Christian WIESMANN , Yan WU
IPC: C07K16/28 , C07K16/30 , A61K39/395
CPC classification number: C07K16/2863 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/3038 , C07K16/3061 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30
Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
-
公开(公告)号：US20170029501A1
公开(公告)日：2017-02-02
申请号：US15053964
申请日：2016-02-25
Applicant: Genentech, Inc.
Inventor： Yan WU , Minhong YAN
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies.
Abstract translation: 本发明提供了抗EphrinB2抗体，组合物和使用这些抗体的方法。
-
公开(公告)号：US20160304613A1
公开(公告)日：2016-10-20
申请号：US14616415
申请日：2015-02-06
Applicant: GENENTECH, INC.
Inventor： Ryan J. WATTS , Yan WU
IPC: C07K16/28 , C07K16/30 , A61K45/06 , C07K16/22 , A61K39/395
CPC classification number: C07K16/2863 , A61K31/404 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/661 , A61K31/69 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K16/22 , C07K16/3023 , C07K2317/31 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
-
公开(公告)号：US20160222117A1
公开(公告)日：2016-08-04
申请号：US14846457
申请日：2015-09-04
Applicant: GENENTECH, INC.
Inventor： Bryan IRVING , Henry CHIU , Heather MAECKER , Sanjeev MARIATHASAN , Sophie M. LEHAR , Yan WU , Jeanne CHEUNG
CPC classification number: C07K16/2827 , A61K31/7068 , A61K39/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/1063 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/3046 , C07K2317/14 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/489 , Y02A50/492 , A61K2300/00
Abstract: The present application relates to nucleic acid encoding anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Abstract translation: 本申请涉及编码抗PD-L1抗体的核酸，其具有治疗用途，其具有增强T细胞功能以上调细胞介导的免疫应答和用于治疗T细胞功能障碍性疾病，包括感染（例如急性和慢性 ）和肿瘤免疫。
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.039 seconds)
